🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Australia / NCT07232160
Starting soon Observational

Is Density Spectral Array Display Along With Bispectral Index Superior to the Display of Bispectral Index Alone

NCT07232160 · tracked via the Priya Life Science Australia tracker
Phase
Observational
Started
2026-06-30
Last updated
2025-11-18

Condition(s) studied

Awareness During General Anesthesia

Investigational drug(s) / intervention(s)

Depth of anesthesia monitoring using processed EEG

Depth of anesthesia monitoring using processed EEG: Comparison of processed EEG monitor (Bispectral index) with and without Density spectral array

Study summary

A study to evaluate the use of density spectral array display in comparison with Bispectral index in a clinical setting.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 65 years undergoing elective procedures of 1-3 hours' duration requiring GA. * Procedures in which a DoA monitor can be applied to the forehead. * Patients receiving intravenous propofol and opiate anaesthesia using supraglottic airway device. * Patient able to provide informed consent. Exclusion criteria: * Administration of ketamine/dexmedetomidine. * Administration of inhaled anaesthetic agents or nitrous oxide * Administration of muscle relaxation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Royal Brisbane and Women's Hospital Herston Queensland

More The University of Queensland trials in Australia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07232160 on ClinicalTrials.gov ↗ ← All trials in Australia